Session 4: Summary and Conclusions

Size: px
Start display at page:

Download "Session 4: Summary and Conclusions"

Transcription

1 Session 4: Summary and Conclusions

2 Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement (PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2) Myelodysplastic/myeloproliferative neoplasms Myelodysplastic syndromes (MDS) Blastic plasmacytoid dendritic cell neoplasm 10 cases Oral #376 (PCM-JAK2 neoplasm) 17 cases Oral #124 (acml), #171 (JMML), #351 (CMML) 12 cases 2 cases Oral #314

3 Myelodysplastic syndromes Case # Submitter Panel Diagnosis Genetic features 60 Tianyu Yang MDS, unclassifiable 46,XX,del(11)(q13q23)[17]/46,XX[3]; CSF3R 88 Elizabeth Margolskee MDS, unclassifiable 45,XY,der(1)t(1;2)(q32;p11.2),der(2;11)(11pter >11q13::2 p11 >2q3?1::11q23 >11qter)[7]/46,XY[13] 289 Ming Xie MDS, unclassifiable 45,XY,inv(3)(q21q26.3),-7[2]/46,XY[19] 305 David Kim Therapy-related MDS 46,XX,t(16;21)(q24;q22)[17]/46,XX[3]; RUNX1-CBFA2T3 218 Kwun Wah MDS-RS with single lineage dysplasia DNMT3A, SF3B1, TET2 280 Catherine Leith MDS-RS with single lineage dysplasia SF3B1 363 Shanxing Zhang MDS with multilineage dysplasia U2AF1 178 Alexandra Kovach MDS with multilineage dysplasia IDH2, SRSF2, JAK2 51 Tianyu Yan MDS with multilineage dysplasia SRSF2, TET2 247 Habibe Kurt MDS with excess blasts-1 (with fibrosis) TP Jay Patel MDS with excess blasts-2 WT1, SMC3, STAG2 296 Payal Sojitra MDS with excess blasts-2 NRAS, WT1

4 What genetic studies should be done to diagnose and classify MDS? Conventional karyotype Evaluate for isolated del(5q)(+/- one other aberration) Evaluate for MDS-defining cytogenetic aberration FISH is usually not indicated if 20 metaphases are obtained SF3B1 mutation Can substitute iron stain if not available, but less sensitive (cases with 5-15% ring sideroblasts may have SF3B1 mutation and appear similar to MDS-RS with >15% ring sideroblasts) TP53 mutation in MDS with isolated del(5q)

5 Cytogenetic findings defining MDS irrespective of morphologic dysplasia Certain mutation patterns in cytopenic patients appear to predict progression to MDS/AML and poor outcome SF3B1/U2AF1/SRSF2/ZRSR2 or TET2/DNMT3A/ASXL1 + one other mutation Real MDS MDS Mutation-defined MDS Malcovati L et al. Blood 2017

6 MDS with isolated del(5q): one other cytogenetic abnormality is OK, but TP53 mutation is bad Mallo M Leukemia 2011;25:110, Jadersten M JCO 2011;29:1971, Germing U Leukemia 2012;26:1286

7 Navigating ring sideroblasts and SF3B1 data in MDS cases with <1% PB and <5% BM blasts Ring sideroblasts SF3B1 mutation Dysplastic lineages 2016 WHO <5% No or unknown One MDS with single lineage dysplasia* <5% Yes One MDS with single lineage dysplasia* <5% No or unknown Two or three MDS with multilineage dysplasia <5% Yes Two or three MDS with multilineage dysplasia 5-14% No or unknown One MDS with single lineage dysplasia* 5-14% Yes One MDS-RS with single lineage dysplasia* 5-14% No or unknown Two or three MDS with multilineage dysplasia 5-14% Yes Two or three MDS-RS with multilineage dysplasia 15% No or unknown One MDS-RS with single lineage dysplasia* 15% Yes One MDS-RS with single lineage dysplasia* 15% No or unknown Two or three MDS-RS with multilineage dysplasia 15% Yes Two or three MDS-RS with multilineage dysplasia *Classified as MDS-U if there is pancytopenia

8 Chronic myeloid leukemia, BCR-ABL1+ Case # Submitter Panel Diagnosis Blood counts Genetic features Birgitta Sander Cameron Yin CML, BCR-ABL1+, in chronic phase ( aleukemic ) CML, BCR-ABL1+, in chronic phase ( aleukemic ) HGB 11.3, WBC 7.0 (no basophilia), PLT 273 HGB 10.5, WBC 6.2 (4% metas, 5% basophils), PLT 197 t(9;22) in 3/8 metaphases, confirmed by FISH 45,X, Y,t(9;22)(q34;q11.2)[20] p210 BCR-ABL1

9 Aleukemic CML #17 5 Yin #77 Sander

10 Myeloproliferative neoplasms Case # Submitter Panel Diagnosis Genetic features 147 Madhu Ouseph Chronic neutrophilic leukemia CSF3R 222 Carmen Winters Chronic neutrophilic leukemia CSF3R, SRSF2, ASXL1 274 Shafinaz Hussein Chronic neutrophilic leukemia SRSF2, GATA2 104 Kristin Karner Essential thrombocythemia MPL 304 David Yang Favor post-et myelofibrosis with dysplastic progression (versus atypical CML, BCR-ABL1-) CALR, SF3B1, KRAS 130 April Chiu 237 Xin Liu 310 Zhihong Hu Myeloproliferative neoplasm, unclassifiable Myeloproliferative neoplasm, unclassifiable (ET versus PV with iron deficiency) Favor overt primary myelofibrosis (with monocytosis) ASXL1, SRSF2, TET2, FLT3-ITD JAK2 MPL, IDH2 361 Xueyan Chen Favor post-pv myelofibrosis JAK2, SF3B1

11 #147 Ouseph WBC 26.4, 84% polys CSF3R p.n713k

12 13 year-old with platelets 753K & Budd- Chiari. JAK2 V617F #237 Liu

13 Monocytosis in MPN versus CMML #310 Hu: 71 year old man with anemia and leukoerythroblastosis, WBC 12.5 with 24% monocytes. Bone marrow with megakaryocyte proliferation typical of PMF, grade 2 of 3 retic and positive trichrome. MPL, IDH2 mutations SSC-A Granulocyte: 57% MFI= Monocytes: 17% -400 Lymphocytes: 21% Myeloblasts: 4% CD45 V500-A B

14 What genetic studies should be done to diagnose and classify MPN (excluding eosinophilias)? Conventional karyotype Confirm clonality, evaluate for t(9;22), evaluate for secondary changes defining accelerated phase in CML BCR-ABL1 by FISH and/or qualitative RT-PCR if CML is suspected; ABL1 mutations if resistant to TKI therapy JAK2 V617F; MPL and CALR if JAK2 negative JAK2 exon12 assessment if suspected PV and JAK2 V617F negative Broader myeloid-mutation NGS panel to confirm clonality in triple negative cases CSF3R in suspected CNL

15 New genetic criteria defining AP in CML Swerdlow SH ed. Revised 4 th edition WHO Classification

16 Case # Submitter Panel Diagnosis Mutations 79 Katherine Devitt Atypical CML, BCR-ABL1 negative DNMT3A, TET2, U2AF1, KMT2A-PTD 124 John Goodlad Atypical CML, BCR-ABL1 negative SRSF2, SETBP1, CSF3R 168 Jim Cook Atypical CML, BCR-ABL1 negative SRSF2, TET2, CSF3R 212 Julia Geyer Atypical CML, BCR-ABL1 negative ASXL1, SETBP1 216 Gerald Penn Atypical CML, BCR-ABL1 negative SRSF2, ASXL1, RUNX1 315 Ashley Cunningham Atypical CML, BCR-ABL1 negative SRSF2, SETBP1, ASXL1, TET2, CSF3R 220 Kedar Inamdar CMML Adam Wood CMML-1 NPM1 351 Madhu Menon CMML-0 SRSF2, TET2, ASXL1 360 David Cantu CMML-1 SRSF2, TET2, ASXL1, JAK2 374 Scott Wendroth CMML-1 SETBP1, EZH2, NRAS, RUNX1 67 Theodore Schultheiss CMML-0 and MGUS CSF3R 122 Omar Khan JMML/Ras-associated autoimmune leukoproliferative disorder KRAS 152 Jie Li JMML PTPN Shunyou Gong JMML PTPN11, KRAS 126 John Goodlad MDS/MPN-RS-T JAK2, SF3B1, TET2 263 Christopher Cogbill MDS/MPN, unclassifiable ASXL1, SRSF2, CBL, GATA2

17 Myelodysplastic/myeloproliferative neoplasms CMML Atypical CML MDS/MPN-U MDS/MPN-RS-T Dysplasia Myeloids Myeloids (severe) Variable Erythroids (RS) Cytopenia Any Any or none Any or none Anemia Proliferation Monos 1 x 10 9 /L WBC 13 x 10 9 /L PLT 450 x 10 9 /L or WBC 13 x 10 9 /L Genetics TET2 50% ASXL1 45% SRSF2 40% RUNX1 15% CBL 15% SETBP1 10% ETNK1 2% TET2 30% SETBP1 25% ASXL1 25% NRAS 20% EZH2 15% ETNK1 9% CBL 8% TET2 30% RUNX1 15% SETBP1 10% NRAS 10% CBL 10% EZH2 10% JAK2 20% PLT 450 x 10 9 /L SF3B1 85% JAK2 60% TET2 25% DNMT3A 15% MPL 10% ASXL1 10% Median OS 31 months 12 months 22 months months Such E et al. Blood 2013;121:3005, Wang SA et al. Blood 2014;123:2645, Zoi K et al. Int J Hematol 2015;101:229, Meggendorfer M et al. Leukemia 2013;27:1852, Broseus J et al. Leukemia 2013;27:1826, Gambacorti-Passerini CB et al. Blood 2015;125:499.

18 What genetic studies should be done to diagnose and classify MDS/MPN? Conventional karyotype Confirm clonality, evaluate for t(9;22) BCR-ABL1 by FISH and/or qualitative RT-PCR to exclude CML Consider a myeloid-mutation NGS panel JAK2, MPL and CALR may suggest progression from a prior MPN JAK2 + SF3B1 common pattern in MDS/MPN-RS-T Mutation pattern can suggest CMML in borderline cases Can help confirm clonality (provided CHIP is excluded)

19 What genetic studies should be done in suspected JMML? Conventional karyotype Confirm clonality (monosomy 7), evaluate for t(9;22) BCR-ABL1 by FISH and/or qualitative RT-PCR PTPN11, KRAS, NRAS (must be somatic, not germline) CBL, NF1 (germline)

20 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Case # Submitter Panel Diagnosis Genetic findings 314 Habibe Kurt BPDCN DNMT3A, TET2 mutations 186 Anna Porwit BPDCN ZRSR2, IDH2, ETV6, PTPRT mutations

21 What genetic studies should be done in suspected blastic plasmacytoid dendritic cell neoplasm? No current genetic tests available for diagnostic purposes

22 Systemic mastocytosis (SM) Case # Submitter Panel Diagnosis Genetic findings 156 Jeffrey Craig 74 Cyrus Oster SM with associated hematologic neoplasm (CMML-0) SM with associated hematologic neoplasm (MDS-RS-SLD) KIT, ASXL1, TET2 mutations SF3B1 mutation (no KIT mutation)

23 What genetic studies should be done in (un)suspected mastocytosis? KIT Should be evaluated on lesional tissue may be absent from blood unless an associated hematologic neoplasm is present Presence of KIT mutation in bone marrow (even if involved by an overt non-mast-cell neoplasm) should stimulate a careful search for occult mast cell disease

24 Myeloid/lymphoid neoplasms (MLN) with eosinophilia and gene rearrangements Case # Submitter Panel Diagnosis Presentation 44 Nadine Aguilera MLN with PDGFRA rearrangement Atypical CML-like 312 Jo-Anne Vergilio MLN with PDGFRA rearrangement Chronic eosinophilic leukemia 349 Kyle Bradley MLN with PDGFRA rearrangement Chronic eosinophilic leukemia 324 Lawrence Low MLN with PDGFRB rearrangement Concurrent AML and T-LBL 75 Koping Chang MLN with FGFR1 rearrangement Concurrent MPN/mast cell proliferation and T-LBL 121 Omar Khan MLN with FGFR1 rearrangement MPN progressed to MPAL 286 Lynh Nguyen MLN with FGFR1 rearrangement MPN progressed to AML 379 Robert Lorsbach MLN with FGFR1 rearrangement B-ALL 32 John Astle MLN with PCM1-JAK2; small clone with PML-RARA, of uncertain significance Chronic eosinophilic leukemia 376 Magdalena Czader MLN with PCM1-JAK2 Chronic eosinophilic leukemia

25 #75: Myeloid/lymphoid neoplasm with FGFR1 rearrangement t(8;13)(p11;q12); ZMYM2 FGFR1 TdT Neck lymph node CD3

26 Bone marrow: Eosinophilia and atypical mast cell proliferation, no KIT mutation

27 Chronic eosinophilic leukemia, NOS Case # Submitter Panel Diagnosis Genetic Lesion 31 Ruijun Su CEL, NOS ETV6-ACSL6, U2AF1 and BRIP1 mutations 146 Madhu Ouseph CEL, NOS TET2 mutation 211 Daniel Socha CEL, NOS SETBP1, EZH2, JAK2, TP53 mutations 300 Geetha Jagannathan CEL, NOS ASXL1 mutation 308 Xiaohui Zhang CEL, NOS DNMT3A mutation

28 What genetic studies should be done to classify eosinophilias? Conventional karyotype Abnormality establishes CEL, NOS diagnosis or a geneticallydefined eosinophilia, also evaluate for t(9;22) to exclude CML BCR-ABL1 by FISH and/or qualitative RT-PCR FIP1L1-PDGFRA by FISH and/or RT-PCR Consider a broad myeloid-mutation NGS panel Can help establish CEL, NOS diagnosis even if karyotype is normal Should include KIT mutation assessment to evaluate for mastocytosis

29 2016 WHO Criteria for CEL, NOS

30 Mutations in idiopathic hypereosinophilias are associated with poor outcome Mutations detected in 21 patients with a diagnosis of CEL, NOS/idiopathic HES Patients ASXL1 TET2 EZH2 DNMT3A NOTCH1 SETBP1 CBL U2AF1 TP53 JAK2 NRAS BCOR GATA2 CSF3R ETV Wang SA et al. Haematologica 2017;102:1352, Wang SA et al. Mod Pathol 2016;29:854

31 Ineffective hematopoiesis Intact maturation BPDCN MDS SF3B1 RAS pathway JMML MDS/MPN ASXL1, SRSF2, SETBP1 MLN-Eo PDGFRA-v FGFR1-v PCM1-JAK2 PDGFRB-v CSF3R JAK2 MPN Effective hematopoiesis Intact maturation BCR-ABL1 MPL CALR KIT Mastocytosis B-ALL AML MPAL T-ALL Arrested maturation Myeloid lineage MLN-Eo MLN-Eo Arrested maturation Lymphoid lineage

Myeloproliferative Neoplasms

Myeloproliferative Neoplasms Myeloproliferative Neoplasms (MPN and MDS/MPN) Attilio Orazi, MD, FRCPath Weill Cornell Medical College/ NY Presbyterian Hospital, New York, NY USA EAHP EDUCATIONAL SESSION: Updated WHO classification

More information

Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated

Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated Attilio Orazi, MD, FRCPath. (Engl.) Professor of Pathology and Laboratory Medicine Weill Cornell Medical College/NYP Hospital New York, NY

More information

Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester

Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present

More information

Case Presentation. Attilio Orazi, MD

Case Presentation. Attilio Orazi, MD Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia

More information

Myelodysplastic syndromes

Myelodysplastic syndromes Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.

More information

SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL

SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL SH2017-0124 A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL NEGATIVE John R Goodlad 1, Pedro Martin-Cabrera 2, Catherine Cargo 2 1. Department of Pathology, NHS Greater Glasgow & Clyde, QEUH, Glasgow 2. Haematological

More information

Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions

Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School

More information

Chronic Myelomonocytic Leukemia with molecular abnormalities SH

Chronic Myelomonocytic Leukemia with molecular abnormalities SH Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient

More information

Approaching myeloid neoplasms: diagnostic algorithms

Approaching myeloid neoplasms: diagnostic algorithms Approaching myeloid neoplasms: diagnostic algorithms Alexandar Tzankov Histopathology Pathology Content Integration of clinical and laboratory data Bone marrow evaluation approaching Myeloproliferative

More information

WHO Update to Myeloproliferative Neoplasms

WHO Update to Myeloproliferative Neoplasms WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories

More information

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.

Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D. Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification

More information

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2

More information

WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities

WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that

More information

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew

More information

Disclosures for Ayalew Tefferi

Disclosures for Ayalew Tefferi Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte

More information

Myelodysplastic syndromes and the new WHO 2016 classification

Myelodysplastic syndromes and the new WHO 2016 classification Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital

More information

Disclosures. I do not have anything to disclose. Shared Features of MPNs. Overview. Diagnosis and Molecular Monitoring in the

Disclosures. I do not have anything to disclose. Shared Features of MPNs. Overview. Diagnosis and Molecular Monitoring in the Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Target Therapy Era C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not have

More information

Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy

Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not

More information

Disclosures for Ayalew Tefferi

Disclosures for Ayalew Tefferi Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte

More information

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic

More information

MDS/MPN MPN MDS. Discolosures. Advances in the Diagnosis of Myeloproliferative Neoplasms. Myeloproliferative neoplasms

MDS/MPN MPN MDS. Discolosures. Advances in the Diagnosis of Myeloproliferative Neoplasms. Myeloproliferative neoplasms Discolosures Advances in the Diagnosis of Myeloproliferative Neoplasms Consulting income from Promedior, Inc. Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical

More information

9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology

9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30

More information

Pathogenesis and management of CMML

Pathogenesis and management of CMML Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure

More information

Heme 9 Myeloid neoplasms

Heme 9 Myeloid neoplasms Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia

More information

SESSION 1 Reactive cytopenia and dysplasia

SESSION 1 Reactive cytopenia and dysplasia SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships

More information

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

Update on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester

Update on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical

More information

Session II: Summary. Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School

Session II: Summary. Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School Session II: Summary Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School Disclosure of speaker s interests (Prefix and Last Name) (Potential) conflict

More information

Disclosures for Ayalew Tefferi

Disclosures for Ayalew Tefferi Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte

More information

Disclosures for Angela Fleischman

Disclosures for Angela Fleischman Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes

More information

WHO Classification 7/2/2009

WHO Classification 7/2/2009 Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks

More information

WHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand

WHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand WHO 2016/17 update on Myeloproliferative Neoplasms Anna Ruskova Auckland City Hospital New Zealand BLOOD, 19 MAY 2016 x VOLUME 127, NUMBER 20 2 2016/17 Classification of Myeloproliferative Neoplasms Chronic

More information

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation

More information

Session 7 Summary. Magdalena Czader, MD, PhD David Czuchlewski, MD MOLECULAR GENETICS OF HEMATOPOIETIC NEOPLASMS

Session 7 Summary. Magdalena Czader, MD, PhD David Czuchlewski, MD MOLECULAR GENETICS OF HEMATOPOIETIC NEOPLASMS Session 7 Summary Magdalena Czader, MD, PhD David Czuchlewski, MD MOLECULAR GENETICS OF HEMATOPOIETIC NEOPLASMS 1 Cases according to 2016 WHO classification Acute myeloid leukemia: 26 AML with recurrent

More information

MDS/MPN: What it is and How it Should be Treated?

MDS/MPN: What it is and How it Should be Treated? MDS/MPN: What it is and How it Should be Treated? MDS MPN Rachel Salit, MD Assistant Member Fred Hutchinson Cancer Research Center rsalit@fredhutch.org MDS Founda>on Pa>ent & Family Forum: May 20, 2017

More information

Disclosures for Ayalew Tefferi

Disclosures for Ayalew Tefferi Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

Out-Patient Billing CPT Codes

Out-Patient Billing CPT Codes Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB

More information

APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE

APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University

More information

Myelodysplastic/Myeloproliferative Disorders. MDS/MPD Unclassified Provisional: CMML JMML acml RARS T. K. Foucar November 2007 SH/EAHP Workshop

Myelodysplastic/Myeloproliferative Disorders. MDS/MPD Unclassified Provisional: CMML JMML acml RARS T. K. Foucar November 2007 SH/EAHP Workshop Myelodysplastic/Myeloproliferative Disorders CMML JMML acml MDS/MPD Unclassified Provisional: RARS T K. Foucar November 2007 SH/EAHP Workshop MDS/MPD: General Features Blood: Cytosis and cytopenia(s) Dysplasia

More information

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Myeloid neoplasms. Early arrest in the blast cell or immature cell we call it acute leukemia Myoid neoplasm divided in to 3 major categories: Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid

More information

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte

More information

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular

More information

Laboratory Service Report

Laboratory Service Report Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe

More information

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE

More information

MYELOPROLIFERATIVE NEOPLASMS

MYELOPROLIFERATIVE NEOPLASMS 9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary

More information

Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML

Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML reprinted from november 2014 pathology laboratory medicine laboratory management Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML CAP TODAY and the Association for Molecular

More information

Supplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia

Supplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína

More information

Conditions that mimic neoplasia in the bone marrow. Kaaren K. Reichard Mayo Clinic Rochester

Conditions that mimic neoplasia in the bone marrow. Kaaren K. Reichard Mayo Clinic Rochester Conditions that mimic neoplasia in the bone marrow Kaaren K. Reichard Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Multiple conditions in

More information

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory

More information

Guidelines for the diagnosis and treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Nordic MDS Group

Guidelines for the diagnosis and treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Nordic MDS Group Guidelines for the diagnosis and treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Nordic MDS Group 8th update, May 2017 1 WRITING COMMITTEE... 4 CONTACT INFORMATION... 4 EVIDENCE

More information

Juvenile Myelomonocytic Leukemia (JMML)

Juvenile Myelomonocytic Leukemia (JMML) Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic

More information

Hematology Unit Lab 2 Review Material

Hematology Unit Lab 2 Review Material Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided

More information

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy. Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine

More information

Hypereosinophili c syndrome

Hypereosinophili c syndrome Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics

More information

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Introduction of an NGS gene panel into the Haemato-Oncology MPN service Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics

More information

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong

More information

West Midlands Regional Genetics Laboratory

West Midlands Regional Genetics Laboratory West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management

More information

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome

More information

Published Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation.

Published Ahead of Print on April 14, 2016, as doi: /haematol Copyright 2016 Ferrata Storti Foundation. Published Ahead of Print on April 14, 2016, as doi:10.3324/haematol.2016.143214. Copyright 2016 Ferrata Storti Foundation. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse

More information

CHALLENGING CASES PRESENTATION

CHALLENGING CASES PRESENTATION CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36

More information

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction

More information

Genetic complexity in MPN, MDS/MPN and MDS

Genetic complexity in MPN, MDS/MPN and MDS Genetic complexity in MPN, MDS/MPN and MDS Nick Cross Wessex Regional Genetics Laboratory, Salisbury Faculty of Medicine, University of Southampton Genetic complexity in chronic myeloid neoplasms Classes

More information

Supervisor: Prof. Dr. P Vandenberghe Dr. C Brusselmans

Supervisor: Prof. Dr. P Vandenberghe Dr. C Brusselmans Contribution of molecular diagnosis in eosinophilia/hypereosinophilia Eosinophilia Hypereosinophilia Hypereosinophilic syndrome Immune mediated hypereosinophilia Chronic eosinophilic leukemia (NOS)/ Idiopathic

More information

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute

More information

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine Michelle Afkhami, M.D. Medical Director, Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center Objectives

More information

Diagnostic Molecular Pathology of Myeloid Neoplasms

Diagnostic Molecular Pathology of Myeloid Neoplasms Diagnostic Molecular Pathology of Myeloid Neoplasms Beirut, Lebanon Tuesday November 29, 2011: Pre-congress workshop Adam Bagg University of Pennsylvania Philadelphia, USA Myeloid neoplasms Myeloproliferative

More information

AML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen

AML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired

More information

The Evolving Role of Transplantation for MPN

The Evolving Role of Transplantation for MPN The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference

More information

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose. RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May

More information

Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases

Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar

More information

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol

More information

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri Myeloproliferative Neoplasms: New Approaches to Diagnosis and Disease Monitoring John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine

More information

August 17, Dear Valued Client:

August 17, Dear Valued Client: August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued

More information

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of

More information

Myelodysplastic Syndrome Case 158

Myelodysplastic Syndrome Case 158 Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was

More information

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms

Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template web posting date: December 2014 Authors Todd W. Kelley, MD, FCAP University of Utah and ARUP Laboratories,

More information

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)

More information

ACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016

ACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016 Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose

More information

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,

More information

ADRL Advanced Diagnostics Research Laboratory

ADRL Advanced Diagnostics Research Laboratory ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New

More information

Laboratory Service Report

Laboratory Service Report Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic

More information

Presenter Disclosure Information

Presenter Disclosure Information Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information

More information

Juvenile and Chronic Myelo-Monocytic Leukemia

Juvenile and Chronic Myelo-Monocytic Leukemia Juvenile and Chronic Myelo-Monocytic Leukemia Haematopoietic stem cell Lympho-myeloid progenitor cell MEP CFU-GM lymphoid progenitor cell BFU-E CFU-MK CFU-E erythro CFU-M CFU-G CFU-T CFU-B MGK red blood

More information

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship

More information

Protocol for the Examination of Hematologic Malignancies in Bone Marrow

Protocol for the Examination of Hematologic Malignancies in Bone Marrow Protocol for the Examination of Hematologic Malignancies in Bone Marrow Version: Bone Marrow 4.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol is recommended

More information

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow 74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint

More information

9/18/2017. Overview reasons an update was necessary. Myeloproliferative neoplasms

9/18/2017. Overview reasons an update was necessary. Myeloproliferative neoplasms 2016 WHO updates to the classification of hematologic neoplasms Darshan Roy, MD Assistant Professor Department of Pathology Director of Hematopathology Rowan School of Osteopathic Medicine Outline Myeloid

More information

ASBMT MDS/MPN Update Sunil Abhyankar, MD

ASBMT MDS/MPN Update Sunil Abhyankar, MD ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine

More information

[COMPREHENSIVE GENETIC ASSAY PANEL ON

[COMPREHENSIVE GENETIC ASSAY PANEL ON 2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for

More information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS

More information

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or

More information

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia

More information

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng

More information

Myelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie

Myelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de

More information